EP4098265A4 - Use of acylated spiramycin in preparation of medicament for treating coronavirus infectious disease - Google Patents

Use of acylated spiramycin in preparation of medicament for treating coronavirus infectious disease Download PDF

Info

Publication number
EP4098265A4
EP4098265A4 EP20916420.1A EP20916420A EP4098265A4 EP 4098265 A4 EP4098265 A4 EP 4098265A4 EP 20916420 A EP20916420 A EP 20916420A EP 4098265 A4 EP4098265 A4 EP 4098265A4
Authority
EP
European Patent Office
Prior art keywords
medicament
preparation
infectious disease
treating coronavirus
coronavirus infectious
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20916420.1A
Other languages
German (de)
French (fr)
Other versions
EP4098265A1 (en
Inventor
Enhong Jiang
Jiandong Jiang
Yongsheng CHE
Yuhuan LI
Dong Wang
Weiqing He
Xiaofeng Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Fuyang Pharmaceutical Technology Co Ltd
Original Assignee
Shenyang Fuyang Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Fuyang Pharmaceutical Technology Co Ltd filed Critical Shenyang Fuyang Pharmaceutical Technology Co Ltd
Publication of EP4098265A1 publication Critical patent/EP4098265A1/en
Publication of EP4098265A4 publication Critical patent/EP4098265A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20916420.1A 2020-01-30 2020-03-25 Use of acylated spiramycin in preparation of medicament for treating coronavirus infectious disease Pending EP4098265A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010077555 2020-01-30
CN202010085611 2020-02-10
PCT/CN2020/081204 WO2021151264A1 (en) 2020-01-30 2020-03-25 Use of acylated spiramycin in preparation of medicament for treating coronavirus infectious disease

Publications (2)

Publication Number Publication Date
EP4098265A1 EP4098265A1 (en) 2022-12-07
EP4098265A4 true EP4098265A4 (en) 2024-03-13

Family

ID=72451312

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20916420.1A Pending EP4098265A4 (en) 2020-01-30 2020-03-25 Use of acylated spiramycin in preparation of medicament for treating coronavirus infectious disease

Country Status (3)

Country Link
EP (1) EP4098265A4 (en)
CN (1) CN111671762B (en)
WO (1) WO2021151264A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021151391A1 (en) * 2020-01-30 2021-08-05 沈阳福洋医药科技有限公司 Application of isovalerylspiramycin compound and composition thereof in preparation of antiviral drug
WO2021169957A1 (en) * 2020-02-24 2021-09-02 上海科技大学 Application of n-substituted pyridyl benzisoselenazolone compound
CN113577086B (en) * 2020-04-30 2023-05-02 沈阳福洋医药科技有限公司 Application of isovaleryl spiramycin compound or composition thereof in preparation of medicines for treating immune disorder
CN114246847B (en) * 2020-09-21 2024-01-16 北京化工大学 Application of chalcone compounds in treatment of coronavirus infection
IT202000022411A1 (en) * 2020-09-23 2022-03-23 Carlo Brogna FORMULATION OF DRUGS OF THE CLASS OF ANTIBIOTICS FOR THE PREVENTION AND TREATMENT OF INFECTIONS DUE TO PHAGIC FORMS OF CORONAVIRUS
IT202000022414A1 (en) * 2020-09-23 2022-03-23 Carlo Brogna PHARMACEUTICAL COMPOUNDS OF THE CLASS OF ANTIBIOTICS AND CHEMOTHERAPICS FOR USE IN THE PREVENTION AND TREATMENT OF CORONAVIRUS DISEASES, SUCH AS COVID-19, IN BOTH HUMAN AND VETERINARY MEDICINE FIELDS.
CN113940930A (en) * 2021-12-06 2022-01-18 西安交通大学 Application of rhamnazin in preparation of novel coronavirus resistant medicines and medicines
CN114181258B (en) * 2021-12-29 2023-10-13 南京师范大学 Nucleoside compounds for antiviral treatment and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104958755A (en) * 2015-06-19 2015-10-07 中山大学 Application of teicoplanin in preparation of drugs for Middle East respiratory syndrome coronavirus
WO2019100689A1 (en) * 2017-11-24 2019-05-31 苏州系统医学研究所 Application of macrolide antibiotic in blocking influenza virus infection
WO2019201268A1 (en) * 2018-04-17 2019-10-24 沈阳福洋医药科技有限公司 Drug used for preventing and/or treating pain and/or fever, combination product, and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1568369A1 (en) * 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
GB0613952D0 (en) * 2006-07-13 2006-08-23 Eco Animal Health Ltd Antiviral agent
CN107281210B (en) * 2016-04-11 2022-09-16 中国医学科学院药物研究所 Application of azithromycin in resisting coronavirus infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104958755A (en) * 2015-06-19 2015-10-07 中山大学 Application of teicoplanin in preparation of drugs for Middle East respiratory syndrome coronavirus
WO2019100689A1 (en) * 2017-11-24 2019-05-31 苏州系统医学研究所 Application of macrolide antibiotic in blocking influenza virus infection
WO2019201268A1 (en) * 2018-04-17 2019-10-24 沈阳福洋医药科技有限公司 Drug used for preventing and/or treating pain and/or fever, combination product, and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021151264A1 *

Also Published As

Publication number Publication date
EP4098265A1 (en) 2022-12-07
CN111671762B (en) 2022-02-22
WO2021151264A1 (en) 2021-08-05
CN111671762A (en) 2020-09-18

Similar Documents

Publication Publication Date Title
EP4098265A4 (en) Use of acylated spiramycin in preparation of medicament for treating coronavirus infectious disease
IL195294A (en) Process for producing high purity safinamide or ralfinamide, use thereof in the preparation of medicaments and pharmaceutical formulations containing them
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
CL2007003514A1 (en) COMPOUNDS DERIVED FROM QUINOLINA; PROCEDURE FOR PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMBINATION; AND USE OF COMPOUNDS TO PREPARE A MEDICINAL PRODUCT TO TREAT BACTERIAL INFECTION.
EP4112050A4 (en) Use of nucleoside compound in treatment of coronavirus infectious diseases
NZ601319A (en) Antiviral combinations involving (4r,12as)-n-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2h-pyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
HK1157337A1 (en)
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
BRPI0812738A2 (en) COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD FOR THE TREATMENT OF A VIRAL INFECTION IN A HUMAN
IL216741A (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating diseases
WO2011041632A3 (en) Combination therapies for the treatment of obesity
EP4094774A4 (en) Use of interferon in preparing drug for preventing coronavirus infection or preventing disease caused by coronavirus infection
IL202111A (en) Formulations for the oral administration of amphotericin b and use thereof in the preparation of medicaments for treating an infectious disease
EP4186496A4 (en) Application of cannabidiol in treatment of coronavirus infections
EP4106752A4 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
WO2007035121A3 (en) Isoflavones for treating mucopolysaccharidoses
EP4117630A4 (en) Treatment of coronavirus infection
EP4144357A4 (en) Traditional chinese medicine composition, and application of preparation of traditional chinese medicine composition in preparing medicine for preventing and/or treating coronavirus disease 2019
UA102219C2 (en) Substotuted pyrazolo-quinazoline derivatives, process for the preparation and use thereof as kinase inhibitors
EP4241781A4 (en) Use of p55pik inhibitor in preparation of drug for treating dry eye disease
EP4121038A4 (en) Compositions and methods for the treatment of coronavirus infection and respiratory compromise
CR20220508A (en) Pharmaceutical composition for preventing or treating epidemic rna viral infectious disease
WO2011009115A3 (en) Combination therapies for the treatment of obesity
CL2007003515A1 (en) COMPOUNDS DERIVED FROM QUINOLINA; PROCEDURE FOR PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL COMBINATION; AND USE OF COMPOUNDS TO PREPARE A MEDICINAL PRODUCT TO TREAT BACTERIAL INFECTION.
CL2007003516A1 (en) COMPOUNDS DERIVED FROM QUINOLINA; PROCEDURE FOR PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL COMBINATION; AND USE OF COMPOUNDS TO PREPARE A MEDICINAL PRODUCT TO TREAT BACTERIAL INFECTION.

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240208

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/18 20060101ALI20240202BHEP

Ipc: A61P 31/14 20060101ALI20240202BHEP

Ipc: A61K 45/06 20060101ALI20240202BHEP

Ipc: A61K 31/7048 20060101AFI20240202BHEP